0001209191-21-064378.txt : 20211115
0001209191-21-064378.hdr.sgml : 20211115
20211115060516
ACCESSION NUMBER: 0001209191-21-064378
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211111
FILED AS OF DATE: 20211115
DATE AS OF CHANGE: 20211115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Booth Andrew
CENTRAL INDEX KEY: 0001834411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39781
FILM NUMBER: 211406016
MAIL ADDRESS:
STREET 1: C/O ABCELLERA BIOLOGICS INC.
STREET 2: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbCellera Biologics Inc.
CENTRAL INDEX KEY: 0001703057
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
BUSINESS PHONE: (604) 559-9005
MAIL ADDRESS:
STREET 1: 2215 YUKON STREET
CITY: VANCOUVER
STATE: A1
ZIP: V5Y 0A1
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-11
0
0001703057
AbCellera Biologics Inc.
ABCL
0001834411
Booth Andrew
C/O ABCELLERA BIOLOGICS INC.
2215 YUKON STREET
VANCOUVER
A1
BRITISH COLUMBIA, CANADA
0
1
0
0
Chief Financial Officer
Common Shares
2021-11-11
4
P
0
53500
14.74
A
53500
D
Common Shares
2021-11-11
4
P
0
14000
14.61
A
130959
I
By spouse
The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.60 and $14.67. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in two transactions at prices $14.67 and $14.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Tryn Stimart, attorney-in-fact
2021-11-15